1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
The role of radiation therapy in the treatment of small cell lung cancer
Lichter A, Bunn P, Ihde D, Cohen M, Makuch R, Carney D, Johnston‐Early A, Minna J, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985, 55: 2163-2175. PMID: 2983875, DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyCyclophosphamideDoxorubicinFollow-Up StudiesHumansLomustineLung NeoplasmsMethotrexateProcarbazineProspective StudiesRadiotherapyRadiotherapy DosageRandom AllocationTime FactorsVincristineWhole-Body IrradiationConceptsSmall cell lung cancerLimited-stage small cell lung cancerProphylactic cranial irradiationCell lung cancerCranial irradiationThoracic irradiationLung cancerExtensive-stage small-cell lung cancerComplete response statusLimited-stage diseaseOptimal treatment approachCombination of chemotherapyMinimum of toxicityLong-term survivalSystemic irradiationSystemic chemotherapyAggressive therapyPartial responseCNS failureResponse statusTreatment protocolOngoing protocolRadiation therapyTreatment approachesPatientsActuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate
Trigg M, Makuch R, Glaubiger D. Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. International Journal Of Radiation Oncology • Biology • Physics 1985, 11: 699-702. PMID: 3838542, DOI: 10.1016/0360-3016(85)90300-1.Peer-Reviewed Original ResearchConceptsEwing's sarcomaIntrathecal methotrexateCNS irradiationProphylactic cranial irradiationGroup of patientsCurrent treatment regimensLack of efficacyNational Cancer InstituteCranial irradiationInitial therapyCNS involvementCNS recurrenceTreatment regimensCNS treatmentIrradiation regimenCancer InstituteActuarial riskSarcomaOverall riskPatientsTherapyMethotrexateRiskCNSInvolvementPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1982
The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes
Radice P, Matthews M, Ihde D, Gazdar A, Carney D, Bunn P, Cohen M, Fossieck B, Makuch R, Minna J. The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes. Cancer 1982, 50: 2894-2902. PMID: 6291745, DOI: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaSmall cell subtypeCell carcinomaResponse rateCombination chemotherapyClinical behaviorLong-term disease-free survivalCentral nervous system metastasesSmall cell carcinoma casesUntreated lung cancer patientsCell subtypesSmall cell lung cancerAggressive chemotherapy protocolsDistinct pathologic variantComplete response rateNervous system metastasesCell bronchogenic carcinomaDisease-free survivalIntensive combination chemotherapySmall cell cancerExtent of diseaseLarge cell carcinomaCell lung cancerLung cancer patientsLarge cell component
1981
Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2
Ihde D, Makuch R, Carney D, Bunn P, Cohen M, Matthews M, Minna J. Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2. American Journal Of Respiratory And Critical Care Medicine 1981, 123: 500-7. PMID: 6263137, DOI: 10.1164/arrd.1981.123.5.500.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaExtensive diseaseCentral nervous systemLimited diseaseCell carcinomaBone marrowNervous systemIntensive induction chemotherapyInvolvement of boneSite of metastasisSoft tissueRadionuclide boneAggressive chemotherapyInduction chemotherapyChest roentgenogramMetastatic diseaseUntreated patientsLiver biopsyStaging procedureDistant metastasisFiberoptic bronchoscopyOpposite lungPrognostic implicationsPhysical examinationPretreatment staging
1979
Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy
Wolf G, Chretien P, Elias E, Makuch R, Baskies A, Spiegel H, Weiss J. Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. The American Journal Of Surgery 1979, 138: 489-500. PMID: 90464, DOI: 10.1016/0002-9610(79)90407-0.Peer-Reviewed Original ResearchConceptsΑ1-acid glycoprotein levelsT cell levelsTumor stageAcute phase proteinsUntreated patientsSerum levelsTumor extentCellular immunityImmune reactivitySquamous carcinomaPhase proteinsGlycoprotein levelsSpecific acute phase proteinsCompletion of chemotherapyClinical tumor stageChronic cigarette smokersΑ1-antitrypsin levelsΑ1-antitrypsinCellular immune parametersNeck squamous carcinomaPreoperative chemotherapyRecurrent carcinomaAlbumin levelsControl patientsRegional metastasesThymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentCyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Cohen M, Ihde D, Bunn P, Fossieck B, Matthews M, Shackney S, Johnston-Early A, Makuch R, Minna J. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Journal Of The National Cancer Institute 1979, 63: 163-70. PMID: 221114.Peer-Reviewed Original ResearchConceptsSmall cell bronchogenic carcinomaResistant drug combinationsCell bronchogenic carcinomaCR rateCombination chemotherapyComplete responseBronchogenic carcinomaDrug combinationsExtensive disease patientsLimited disease patientsProtocol-eligible patientsHigh-dose cyclophosphamideBrain radiation therapyDisease-free survivalComplete respondersDrug regimensProlong survivalInitial treatmentRadiation therapyPatientsVP-16ChemotherapyCarcinomaSequential useMonths